As of November 6, 2026, Werewolf Therapeutics, Inc. is a publicly traded company (Nasdaq: HOWL); its largest reported holder is Moll Peter, with 5.2% on Schedule 13G of September 21, 2026 (Schedule 13G, September 21, 2026).
Is this your company?
About to sign with, pay or invest in Werewolf Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Werewolf Therapeutics, Inc. a real, registered company?
- Werewolf Therapeutics, Inc. files with the SEC under CIK 1785530 (its SEC filings).
- Its shares are listed under the ticker HOWL on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Werewolf Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-02-13).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Moll Peter (filed 2026-09-21).
Who are Werewolf Therapeutics, Inc.'s owners and officers?
Werewolf Therapeutics, Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-09-21).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-09-21 | Moll Peter | 5.2% |
| Schedule 13D/A, 2026-07-02 | Ra Capital Management, L.P. | 4.1% |
| Schedule 13D/A, 2026-06-26 | Ra Capital Management, L.P. | 6% |
| Schedule 13D/A, 2026-06-22 | Ra Capital Management, L.P. | 7.5% |
| Schedule 13D/A, 2026-06-15 | Ra Capital Management, L.P. | 10.6% |
| Schedule 13D/A, 2026-05-14 | Ra Capital Management, L.P. | 12.6% |
| Schedule 13D/A, 2026-05-12 | Mpm Bioventures 2014, L.P. | 3.8% |
| Schedule 13D/A, 2026-05-05 | Mpm Bioventures 2014, L.P. | 5.4% |
| Schedule 13G/A, 2026-02-11 | Longwood Fund Iii Gp, LLC | 3.5% |
| Schedule 13D/A, 2026-01-16 | Mpm Bioventures 2014, L.P. | 6.9% |
| Schedule 13D/A, 2025-12-29 | Mpm Bioventures 2014, L.P. | 8.2% |
| Schedule 13D/A, 2025-12-03 | Mpm Bioventures 2014, L.P. | 10% |
Questions about who owns Werewolf Therapeutics, Inc.
Who owns Werewolf Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Werewolf Therapeutics, Inc.: Moll Peter (5.2%, Schedule 13G, filed 2026-09-21).
When did Moll Peter buy into Werewolf Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Moll Peter on this page is the Schedule 13G, filed 2026-09-21, reporting 5.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Werewolf Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Werewolf Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Werewolf Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Werewolf Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- RA Capital Nexus Fund II, L.P., a director and 10% owner: 6,237,482 shares (12.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-05-14).
- MPM BioVentures 2014, L.P.: 4,784,111 shares (9.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-04).
- MPM BioVentures 2014 (B), L.P.: 4,784,111 shares (9.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-04).
- MPM BioVentures 2014 LLC: 4,784,111 shares (9.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-04).
- MPM Asset Management Investors BV2014 LLC: 4,784,111 shares (9.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-04).
Shares outstanding: 48,599,066 as of 2026-07-27, from the company's latest SEC cover page.
How much has Werewolf Therapeutics, Inc. raised?
No fundraising or offering filing from Werewolf Therapeutics, Inc. is on file with us.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-02-13).
Keep reading
More on Werewolf Therapeutics, Inc. and the records around it.
Werewolf Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Layoff notices Feb 2026
Companies that share a holder
- MPM BioVentures 2014, L.P. also filed stake reports on 1 other company: ENTRADA THERAPEUTICS, INC. (Sep 2026)
- PFM Health Sciences, LP also filed stake reports on 2 other companies: Outset Medical, Inc. (Feb 2026), PMV Pharmaceuticals, Inc. (Aug 2025)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/werewolf-therapeutics